🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Jinan
Clinical trial register · China

Clinical Trials in Jinan, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Qilu Hospital of Shandong University114 Qianfoshan Hospital32 Shandong Cancer Hospital and Institute31 AstraZeneca26 Shandong University26
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Jinan

785 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Study of TY-2699a in Patients With Locally Advanced or Metastatic Solid Tumors
NCT05866692Solid Tumor, Adult
TYK Medicines, Inc
Phase 1
156
Beijing, Jinan
2023-08-17
Active, closed
A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies
NCT05885555Primary Immune Thrombocytopenia (ITP)
DrugIanalumab
Novartis Pharmaceuticals
Phase 2
41
Wuhan, Beijing, Jinan
2023-08-16
Active, closed
CS0159 in Chinese Patients With PSC (Primary Sclerosing Cholangitis)
NCT05896137Primary Sclerosing Cholangitis
DrugCS0159
Cascade Pharmaceuticals, Inc
Phase 2
50
Hefei, Beijing, Wuhan, Changsha, Changchun, Jinan, Shanghai, Hangzhou
2023-08-07
Recruiting
A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT05924750Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
DrugBL-M11D1
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
130
Hefei, Beijing, Haerbin, Shenyang, Jinan, Shanghai, Chengdu, Tianjin
2023-08-02
Recruiting
Epidemiological Study of Osteoporosis in the Elderly Population of Shandong Province
NCT06915935Osteoporosis, Osteoporosis (Senile)
The Second Hospital of Shandong University
Observational
2,000
Jinan
2023-08-01
Recruiting
A Multicenter Prospective Study of Risk Factors in Progressive Pulmonary Fibrosis
NCT05895409Interstitial Lung Disease
Qianfoshan Hospital
Observational
610
Jinan
2023-07-27
Active, closed
XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.
NCT06792435Pancreatic Adenocarcinoma Metastatic, Lung Cancer (NSCLC), Ovarian Cancer, Colorectal Cancer Metastatic
Astellas Pharma Global Development, Inc.
Phase 1/2
240
Jinan
2023-07-27
Recruiting
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
NCT05727176Advanced Cholangiocarcinoma, FGFR2 Fusions, Gene Rearrangement
Taiho Oncology, Inc.
Phase 2
120
Guangzhou, Harbin, Nanjing, Changchun, Jinan, Shanghai, Chengdu, Hangzhou
2023-07-05
Recruiting
Endocrine Glucose & Lipids Metabolism and Brain Aging: a Longitudinal Study
NCT06066775Brain Aging Related Conditions
Shandong Provincial Hospital
Observational
10,000
Jinan
2023-07-04
Active, closed
A Digital Tongue Diagnosis Model for High- and Low-risk Esophagogastroduodenal Varices in Cirrhosis
NCT05979935Esophageal Varices, Liver Cirrhosis, Sublingual Varices, Portal Hypertension
Qilu Hospital of Shandong University
Observational
1,300
Jinan
2023-07-01
Recruiting
RC48-ADC Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 Expression
NCT05940896Solid Tumor
DrugDisitamab Vedotin
RemeGen Co., Ltd.
Phase 1
24
Jinan
2023-06-29
Recruiting
Long-term Success Rate of Transvaginal Mesh for the Treatment of Pelvic Organ Prolapse: The Extended RCT Study
NCT05938881Pelvic Organ Prolapse
Peking Union Medical College Hospital
Observational
336
Foshan, Guangzhou, Changsha, Wuxi, Jinan, Xi’an, Chengdu, Ürümqi
2023-06-29
Active, closed
Phase I-II Clinical Trial of Utidelone Capsule in Patients With Advanced Solid Tumors
NCT05700084Advanced Solid Tumor
Beijing Biostar Pharmaceuticals Co., Ltd.
Phase 1/2
84
Beijing, Chengdu, Guangzhou, Jinan, Shanghai, Shenyang, Shijiazhuang, Wuhan
2023-06-09
Recruiting
Safety and Efficacy of Cera™ Patent Foramen Ovale Occluders.
NCT05774288Patent Foramen Ovale, Cryptogenic Stroke
Lifetech Scientific (Shenzhen) Co., Ltd.
Not applicable
244
Beijing, Guangzhou, Meizhou, Changsha, Changchun, Shenyang, Jinan, Kunming
2023-06-08
Recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
NCT05646862Breast Cancer
DrugsOmeprazole·Bupropion·Alpelisib·Inavolisib
Hoffmann-La Roche
Phase 3
420
Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang
2023-06-07
Recruiting
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
NCT05797168Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer, Lung Squamous Cell Carcinoma
DrugsTorvutatug samrotecan·Palacaparib·Paraplatin·Saruparib
AstraZeneca
Phase 1/2
602
Chengdu, Chongqing, Guangzhou, Jinan, Xi'an, Zhengzhou
2023-06-05
Active, closed
A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC
NCT05844150SCLC
DrugsPumitamig·Etoposide
Biotheus Inc.
Phase 2
50
Beijing, Changchun, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Jinan
2023-06-01
Recruiting
Magnetocardiography in the Accurate Identification of Myocardial Infarction
NCT05896826Chest Pain, Acute Coronary Syndrome, Myocardial Infarction
Qilu Hospital of Shandong University
Observational
3,841
Jinan
2023-06-01
Recruiting
A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With Double Expression Diffuse Large B-cell Lymphoma
NCT05933967The First Affiliated Hospital of Nanchang University
DrugsR-Chop·Orelabrutinib
Shandong Cancer Hospital and Institute
Phase 2
31
Nanchang, Jinan
2023-06-01
Recruiting
A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer
NCT05859750Pancreatic Cancer
Drugs5-Fluorouracil/Leucovorin·Cadonilimab·Irinotecan·Nab-paclitaxel
Akeso
Phase 2
78
Beijing, Guangzhou, Wuhan, Jinan, Shanghai, Hangzhou
2023-05-25
Recruiting
Efficacy and Safety of Tislelizumab Plus Chemotherapy as Conversion Therapy in Unresectable Locally Advanced ESCC
NCT07549100Locally Advanced Esophageal Squamous Cell Carcinoma
DrugTislelizumab
Shandong Provincial Hospital
Observational
30
Jinan
2023-05-15
Active, closed
A Study of Molecular Residual, Dynamic Monitoring and Recurrence of Stage III Driver Mutated NSCLC
NCT06443684Non Small Cell Lung Cancer
Shanghai Chest Hospital
Observational
305
Hefei, Xiamen, Guangzhou, Harbin, Zhengzhou, Changsha, Jinan, Shanghai
2023-05-08
Recruiting
Pancreatic Cancer Screening Through the Detection of Elastase-1 Combined With Other Examinations
NCT06041009Pancreatic Ductal Adenocarcinoma, Pancreatic Diseases, Pancreatic Elastase 1, Pancreatic Neuroendocrine Tumor
Qilu Hospital of Shandong University
Observational
2,100
Jinan
2023-05-05
Recruiting
A Study of BPI-460372 in Advanced Solid Tumor Patients
NCT05789602Advanced Solid Tumor
Betta Pharmaceuticals Co., Ltd.
Phase 1
82
Beijing, Baoding, Harbin, Wuhan, Changsha, Changchun, Jinan, Taizhou
2023-04-24
Recruiting
Second-line Treatment of Metastatic Colorectal Cancer
NCT06242067Metastatic Colorectal Cancer
DrugTrifluridine/Tipiracil
Qilu Hospital of Shandong University
Phase 2
50
Jinan
2023-04-23
Recruiting
Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer
NCT06702995Metastatic Castrate-Resistant Prostate Cancer, mCRPC (Metastatic Castration-resistant Prostate Cancer)
DrugsXNW5004·Enzalutamide
Evopoint Biosciences Inc.
Phase 1/2
307
Jinan, Shanghai
2023-04-19
Recruiting
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
NCT05786924Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, BRAF Gene Mutation
DrugsPanitumumab·Folfiri·Nab-paclitaxel·Gemcitabine
Institut de Recherches Internationales Servier
Phase 1/2
554
Beijing, Jinan, Shanghai, Suzhou
2023-04-18
Recruiting
Single-Arm Exploratory Study of PD-L1 Antibody Plus Neoadjuvant Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT07055841Squamous Cell Carcinoma of Head and Neck
DrugAdebrelimab
Xiuping Ding
Phase 2
69
Jinan
2023-04-01
Recruiting
Corona Virus Disease 2019 Cohort Study
NCT06927622COVID-19 Pneumonia, COVID-19 Pandemic, COVID-19
Shandong University
Observational
1,000
Jinan
2023-04-01
Active, closed
A Study of the Clinical Benefit of Tobramycin Inhalation Solution
NCT06106789Bronchiectasis, Cystic Fibrosis, Lung Infection
Qianfoshan Hospital
Observational
1,600
Jinan
2023-04-01
Recruiting
Clinical Application of Wearable Magnet Tracking System for Capsule Endoscopes
NCT05546346Capsule Endoscopes
Qilu Hospital of Shandong University
Not applicable
10
Jinan
2023-03-30
Recruiting
A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors
NCT05718895Advanced/Metastatic Solid Tumors
DrugATG-022
Antengene Biologics Limited
Phase 1
156
Beijing, Chengdu, Fuzhou, Hefei, Jinan, Lanzhou, Qingdao, Shanghai
2023-03-27
Active, closed
Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors
NCT05744427Advanced Solid Tumor
DrugJSKN003
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 1/2
725
Beijing, Changsha, Fuzhou, Guangzhou, Hangzhou, Ha’erbin, Hefei, Jinan
2023-03-15
Active, closed
Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC
NCT05765825Extensive-stage Small-cell Lung Cancer
DrugsSerplulimab·Etoposide·Cisplatin·Carboplatin
Sichuan University
Phase 2
61
Chongqing, Shantou, Wuhan, Shenyang, Jinan, Shanghai, Chengdu, Guiyang
2023-03-07
Active, closed
Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy
NCT05585580Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
DrugsSerplulimab·Lenvatinib
Qilu Hospital of Shandong University
Phase 2
59
Jinan, Qingdao, Yantai, Linyi
2023-03-01
Recruiting
Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer
NCT05765877Non-Small Cell Lung Cancer(NSCLC)
Pingping Song
Phase 2
26
Jinan
2023-03-01
Active, closed
Plasma Proteomics Study of End-Stage Liver Disease Patients Based on Olink Technology
NCT06865898HBV Related Acute-on-chronic Liver Failure
Qilu Hospital of Shandong University
Observational
58
Jinan
2023-03-01
Recruiting
Efficacy and Safety of Apantamide Combined With Docetaxel and ADT vs. Apantamide Combined With ADT in Patients With High Tumor Burden mHSPC: a Multicenter and Prospective Cohort Study
NCT05713578Cohort Studies
Qilu Hospital of Shandong University
Phase EARLY_PHASE1
220
Jinan
2023-03-01
Recruiting
Domestic Violence Enhanced Perinatal Care Program in China
NCT05388565Intimate Partner Violence
University of Texas at Austin
Not applicable
100
Jinan
2023-02-25
Recruiting
A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma
NCT05800977Relapsed/Refractory Large B-Cell Lymphoma
Shanghai AbelZeta Ltd.
Phase 1/2
112
Beijing, Chongqing, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Shanghai
2023-02-22
Recruiting
Effect of Esmolol on Oxygenation Index in Patients With Acute Respiratory Distress Syndrome
NCT06013319Acute Respiratory Distress Syndrome
Zhiming Jiang
Phase 3
178
Jinan
2023-02-20
Active, closed
Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC
NCT05557838Hepatocellular Carcinoma
DrugsTremelimumab·Durvalumab
AstraZeneca
Phase 3
214
Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan
2023-02-15
Active, closed
A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A
NCT05685238Haemophilia A, Haemophilia A With Inhibitors
Novo Nordisk A/S
Phase 3
451
Beijing, Guangzhou, Wuhan, Changsha, Jinan, Chengdu, Tianjin, Huzhou
2023-02-13
Active, closed
First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer
NCT05586061HER2-positive Gastric Cancer
DrugsS1·Disitamab Vedotin·Tislelizumab
Qilu Hospital of Shandong University
Phase 2
55
Jinan, Qingdao, Yantai
2023-02-10
Recruiting
Effects of Low-dose Esmolol on Myocardial Injury After Non-cardiac Surgery in Elderly Frail Patients
NCT05635877Frailty, Esmolol, Myocardial Injury
DrugEsmolol
Yongtao Sun
Phase 4
2,000
Jinan
2023-02-07
Recruiting
Effect of Different Administration Routes of Dexmedetomidine Combined with Ultrasound-Guided Fascia Iliaca Block on Emergence Agitation After Hip Replacement Surgery
NCT06614010Dexmedetomidine, Fascia Iliaca Block
Qianfoshan Hospital
Phase 1
207
Jinan
2023-02-05
Active, closed
A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids
NCT05653219Primary Immune Thrombocytopenia
DrugsEltrombopag·Ianalumab
Novartis Pharmaceuticals
Phase 3
152
Guangzhou, Wuhan, Binzhou, Hangzhou, Beijing, Jinan, Tianjin
2023-02-02
Active, closed
A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia
NCT05662319Hemophilia
DrugsAntithrombin·Clotting factor concentrates·Fitusiran
Sanofi
Phase 3
91
Beijing, Guangzhou, Jinan
2023-02-01
Recruiting
Registry Study for Optimal Management of Liver Failure in the Chinese Population
NCT05740696Liver Failure
First Affiliated Hospital Xi'an Jiaotong University
Observational
500
Xi'an, Ankang, Changsha, Hanzhong, Jinan, Lanzhou, Weinan, Xianyang
2023-01-06
By invitation
Prolonged Extubation in Gastric Cancer With OSA
NCT07362706Obstructive Sleep Apnea, Gastric Cancer (GC)
Qilu Hospital of Shandong University
Observational
240
Jinan
2023-01-01
Recruiting
The Roles of Exosomal Circ-LRBA and 451/CRTC2 Signaling Axis in Colorectal Cancer
NCT05579353Colorectal Cancer
Jingbo Chen
Observational
200
Jinan
2023-01-01
Not yet open
A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma
NCT05590572Osteosarcoma
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 1/2
148
Beijing, Jinan, Shanghai
2023-01
Recruiting
TAA06 Injection in the Treatment of Patients With B7-H3-positive Relapsed/ Refractory Neuroblastoma
NCT05562024B7-H3-positive Relapsed/ Refractory Neuroblastoma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase 1
24
Jinan, Tianjin
2022-12-30
Active, closed
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
NCT05687266NSCLC
DrugsDatopotamab deruxtecan·Dato-DXd·Durvalumab·Pemetrexed
AstraZeneca
Phase 3
1,350
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hefei, Jinan, Kunming
2022-12-29
Recruiting
Clinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer
NCT05653453Locally Advanced Pancreatic Cancer
Jiangsu Healthy Life Innovation Medical Technology Co., Ltd
Phase 3
512
Harbin, Jinan, Shanghai
2022-12-20
Recruiting
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
NCT05490472Solid Tumors, ER+ Breast Cancer, Triple Negative Breast Cancer, TNBC, ARID1A Gene Mutation
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2
102
Beijing, Changchun, Jinan
2022-12-20
Recruiting
Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC
NCT06241807IMMUNOTHERAPY, Neoadjuvant Therapy, Resectable Lung Non-Small Cell Carcinoma, Biomarkers / Blood
DrugTislelizumab
Shandong Cancer Hospital and Institute
Phase 2
30
Jinan
2022-12-02
Recruiting
Promotion and Application of a New Three-level Etiological Diagnosis Strategy for Fever Clinics in Respiratory Infectious Diseases
NCT05965128Respiratory Infectious Diseases
Huashan Hospital
Observational
1,255
Lanzhou, Harbin, Hohhot, Suzhou, Xuzhou, Shenyang, Jinan, Jining
2022-12-01
Active, closed
Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
NCT05556096Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.
Phase 3
260
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Hangzhou, Jinan, Qingdao
2022-11-21
Active, closed
Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC
NCT05374603Lung Cancer
DrugsSavolitinib·Durvalumab
AstraZeneca
Phase 2
47
Beijing, Changsha, Chongqing, Hangzhou, Jinan, Kunming, Nanchang, Ningbo
2022-11-15
Active, closed
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)
NCT05170204Non-Small Cell Lung Cancer
DrugsEntrectinib·Alectinib·Durvalumab
Hoffmann-La Roche
Phase 3
68
Changsha, Chongqing, Jinan, Shanghai
2022-11-01
Recruiting
The Management of Metastatic Neck Nodes in N2/3 Hypopharyngeal Squamous Cell Carcinoma
NCT05494190Hypopharyngeal Carcinoma
DrugsCapecitabine·Cisplatin·Paclitaxel
Eye & ENT Hospital of Fudan University
Not applicable
111
Harbin, Jinan, Shanghai
2022-11-01
Recruiting
Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients
NCT05377034Locally Advanced Hepatocellular Carcinoma
National Cancer Centre, Singapore
Phase 2
100
Beijing, Chengdu, Jinan
2022-10-26
Active, closed
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
NCT05502237Non-small Cell Lung Cancer
DrugsDomvanalimab·Zimberelimab·Nab-paclitaxel·Pemetrexed
Gilead Sciences
Phase 3
1,021
Chengdu, Chongqing, Deyang, Fuzhou, Guangzhou, Hangzhou, Jiangxi, Jinan
2022-10-12
Active, closed
HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma
NCT06239532Intrahepatic Cholangiocarcinoma
Qilu Hospital of Shandong University
Phase 2
28
Jinan
2022-09-27
Recruiting
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT05327114Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
DrugNipocalimab
Janssen Research & Development, LLC
Phase 2/3
201
Beijing, Changchun, Changsha, Chengdu, Chifeng, Fuzhou, Guangzhou, Jinan
2022-09-23
Recruiting
Proteomics and Metabolomics of Body Fluid in Patients With Narcolepsy
NCT06279247Narcolepsy
Qilu Hospital of Shandong University
Observational
60
Jinan
2022-09-01
Recruiting
Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL
NCT05495035Lymphoblastic Leukemia, Acute, Childhood, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Relapsed Leukemia, Refractory Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
19
Hefei, Jinan, Tianjin, Shanghai
2022-09-01
Recruiting
A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors
NCT05417321Advanced Solid Tumor, NSCLC
Shanghai Huaota Biopharmaceutical Co., Ltd.
Phase 1/2
80
Jinan
2022-08-25
Recruiting
A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2-Positive/Negative Breast Cancer and Other Solid Tumors
NCT05461768Breast Cancer, Locally Advanced or Metastatic Solid Tumor
DrugBL-M07D1
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
348
Fuzhou, Dongguan, Guangdong, Zhengzhou, Wuhan, Jinan, Hangzhou
2022-08-09
Recruiting
TreAtments and outComes in paTients With prImary CutAneous Lymphoma
NCT05518851Primary Cutaneous Lymphoma
Peking University First Hospital
Observational
3,000
Beijing, Guandong, Nanjing, Jinan
2022-08-01
Not yet open
Intervention of Suxiao Jiuxin Pill on Instability of Vulnerable Plaque in Acute Myocardial Infarction
NCT05466968Acute Myocardial Infarction
Xiaolu Li
Phase 4
116
Jinan
2022-08-01
Active, closed
A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC
NCT05918133TNBC
DrugsPumitamig·Nab-paclitaxel
Biotheus Inc.
Phase 1/2
42
Chongqing, Harbin, Nanjing, Nanchang, Jinan, Shanghai, Yibin, Tianjin
2022-07-01
Active, closed
A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC
NCT05319431Unresectable, Non-metastatic Hepatocellular Carcinoma
DrugsCadonilimab·Lenvatinib
Akeso
Phase 2
60
Beijing, Guangzhou, Zhengzhou, Changsha, Jinan
2022-06-28
Active, closed
Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer
NCT05132075Non-Small Cell Lung Cancer
DrugsJDQ443·Paclitaxel
Novartis Pharmaceuticals
Phase 3
95
Fuzhou, Guangzhou, Harbin, Changsha, Shengyang, Jinan, Hangzhou, Beijing
2022-06-15
Recruiting
Efficacy and Safety of Long-term Oral Staphylococcus Albicans Tablets in Patients With Bronchiectasis
NCT05407792Bronchiectasis
Qianfoshan Hospital
Not applicable
134
Jinan
2022-06-06
Recruiting
Efficacy and Safety Analysis of Polylauric Alcohol More Stable Foam Versus Ordinary Foam in the Treatment of Head and Neck Venous Malformations
NCT07066527Venous Malformation
Qilu Hospital of Shandong University
Not applicable
110
Jinan
2022-06-01
Recruiting
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
NCT05183646FSGS
DrugDMX-200
Dimerix Bioscience Pty Ltd
Phase 3
286
Baotou, Beijing, Chengdu, Guangzhou, Hangzhou, Hohhot, Jinan, Nanchang
2022-05-30
Active, closed
A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC
NCT05879068SCLC
DrugsPumitamig·Paclitaxel
Biotheus Inc.
Phase 2
99
Beijing, Changchun, Changsha, Chengdu, Hangzhou, Harbin, Jinan, Nanchang
2022-05-27
Recruiting
Patient's Whole Process Follow-up Management(HOPE-1)
NCT05339568Locally Advanced Non-Small Cell Lung Cancer, Metastatic NSCLC
Qianfoshan Hospital
Observational
1,268
Jinan
2022-05-22
Recruiting
A Study to Investigate the Safety and Tolerability of SCR-6920 Capsule in Patients With Advanced Malignant Tumors
NCT05528055Solid Tumor, Non Hodgkin Lymphoma
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
122
Jinan
2022-05-18
Recruiting
Multi-center Study on New Cardiovascular Remodeling and Function Parameters in Hypertension
NCT05638503Hypertension
Qilu Hospital of Shandong University
Observational
2,200
Jinan
2022-05-01
Recruiting
Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
NCT05294055Multiple Myeloma, Lymphoma
DrugsEtoposide·Cyclophosphamide
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
120
Hefei, Beijing, Zhengzhou, Jinan, Tianjin
2022-04-26
Active, closed
A Study of ILB2109 in Patients With Advanced Solid Malignancies
NCT05278546Advanced Solid Tumor
Innolake Biopharm
Phase 1
48
Jinan, Shanghai
2022-04-11
By invitation
Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)
NCT05248659Immunoglobulin A Nephropathy
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 2/3
600
Beijing, Guangzhou, Changsha, Wuxi, Nanchang, Jinan, Chengdu, Yibin
2022-04-05
Active, closed
Olorofim Aspergillus Infection Study
NCT05101187Invasive Aspergillosis
F2G Biotech GmbH
Phase 3
225
Bengbu, Wuhan, Nanchang, Jinan, Shanghai, Xiaobailou, Wenzhou, Beijing
2022-03-31
Active, closed
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
NCT05277051Neoplasms
DrugsGSK5764227·Remzistotug·Nelistotug·Belrestotug
GlaxoSmithKline
Phase 1
152
Chengdu, Jinan, Shanghai, Wuhan
2022-03-22
Recruiting
Application of AI Technology for the Diagnosis and Treatment of Geriatric Diseases
NCT06295263Parkinson Disease, Alzheimer Disease, Nervous System Diseases, Geriatric Diseases
Qilu Hospital of Shandong University
Observational
460
Jinan
2022-03-01
Active, closed
Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis
NCT05138133Lupus Nephritis
DrugAnifrolumab
AstraZeneca
Phase 3
363
Beijing, Bengbu, Chengdu, Guangzhou, Haikou, Hangzhou, Jinan, Jining
2022-02-15
Recruiting
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor
NCT05262491Gastrointestinal Tumor
DrugIza-bren
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
96
Beijing, Nanchang, Jinan, Chengdu, Tianjin, Hangzhou
2022-02-14
Recruiting
Novel Biomarkers of Hypoxia and Metabolism in Clear Cell Renal Cell Carcinoma
NCT05214885Clear Cell Renal Cell Carcinoma
Qianfoshan Hospital
Observational
300
Jinan
2022-02-11
Recruiting
PROfiling Based Endometrial Cancer Adjuvant Therapy
NCT05179447Endometrial Cancer Stage I, Endometrial Cancer Stage II
Women's Hospital School Of Medicine Zhejiang University
Not applicable
590
Wuhan, Jinan, Hangzhou, Beijing, Changsha, Guangzhou, Ningbo, Shanghai
2022-01-24
Recruiting
Prospective Coronary Heart Disease Cohort
NCT05699629Coronary Heart Disease, Myocardial Infarction
Shandong First Medical University
Observational
50,000
Jinan
2022-01-21
Recruiting
First-Line and Neoadjuvant Immunotherapy for Gastric Cancer
NCT06727981Advanced Gastric Cancer, Locally Advanced Gastric Carcinoma
DrugChemothearpy
Qilu Hospital of Shandong University
Observational
500
Jinan
2022-01-15
Active, closed
A Phase I Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors
NCT05114759Advanced Solid Tumors
DrugSHR-A2009
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1
176
Chongqicun, Fuzhou, Guangzhou, Changsha, Nanchang, Changchun, Jinan, Xi’an
2022-01-04
Recruiting
Tubeless Intersegmentectomy Plane Identification With Fluorography
NCT05479825Operation Time, Postoperative Complications
The Second Hospital of Shandong University
Not applicable
60
Jinan
2022-01-01
Recruiting
Validation of CAGIB Score for In-hospital Mortality of Cirrhotic Patients With Acute Gastrointestinal Bleeding
NCT04662918GastroIntestinal Bleeding
Xingshun Qi
Observational
3,000
Beijing, Fuzhou, Wuhan, Nanchang, Dalian, Shenyang, Xi'an, Jinan
2022-01-01
Not yet open
Chemoradiotherapy Sequenced Radical Surgery for Colorectal Cancer With PALNM
NCT05129774Colorectal Neoplasms Malignant, Lymph Node Excision, Chemoradiotherapy
Qilu Hospital of Shandong University
Not applicable
40
Jinan
2022-01-01
Recruiting
The Clinical Efficacy of Immunomodulators in RA Patients
NCT05626348Arthritis, Rheumatoid
DrugsLeflunomide·Iguratimod·Hydroxychloroquine·Adalimumab
Qilu Hospital of Shandong University
Phase 4
400
Jinan
2021-12-22
Active, closed
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT04819100Carcinoma, Non-Small-Cell Lung
DrugSelpercatinib
Eli Lilly and Company
Phase 3
152
Beijing, Fuzhou, Guangzhou, Harbin, Changsha, Changchun, Xi'an, Jinan
2021-12-20
Rows per page Showing 601–700 of 785
Previous 5 6 7 8 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/jinan?page=7

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 785 of those studies with a site in Jinan.

How many clinical trials are recruiting in Jinan?

488 of the 785 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 130 have not yet opened recruitment, 149 are active but closed to new participants, and 18 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.